Active Clinical Trials
For general information regarding clinical trials please contact:Debbie Hannah - 919-681-5797
Contact Dr. Hall’s office at 919-681-8368 for more information on these studies:
1. Active Pemphigus: A Phase I, Open-Label, Multicenter Trial Exploring the Safety and Tolerability of Autologous Polyclonal Regulatory T Cell Therapy in Adults with Active Pemphigus.
2. Pemphigus Vulgaris or Pemphigus Foliaceus: A Phase 1b/2, Multicenter, Open-Label, Safety, and Dose Finding Study of SYNT001 in Subjects with Pemphigus (Vulgaris or Foliaceus)
Contact Dr. Cardones' Office at 919-684-1830 for more information on these trials:
1. Morphea: Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea
2. Atopic Dermatitis: Effect of Dupilumab (anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis.
Contact Dr. Murray's Office at 919-684-1830 for more information on this trial:
1. Plaque Psoriasis: A Multi-Center, Randomized, Double-Blind, Placebo-and Active Comparator-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of BMS-986165 in Subjects with Moderate-to-Severe Plaque Psoriasis
Contact Dr. Olsen's Office at 919-668-5610 for more information on the following studies:
1. Alopecia Areata: A Randomized, Double-blind, Vehicle-controlled Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily for 6 Months in Adult Subjects with Stable Patchy Alopecia Areata
2. Mycosis Fungoides/CTCL: A randomized, double-blind, multi-centre, placebo-controlled, parallel-arm phase 2 trial to assess safety, efficacy and pharmacokinetics of CD11301 0.03% and 0.06% gel in the treatment of Cutaneous T-Cell Lymphoma(CTCL), stages IA, IB and IIA
3. Mycosis Fungoides or Sézary Syndrome/CTCL: A Double Blind, Randomized, Vehicle Controlled, Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion, 0.5%, for the Relief of Pruritus in Patients with the Mycosis Fungoides (MF) or Sézary Syndrome (SS) Forms of Cutaneous T-Cell Lymphoma (CTCL)
Contact Dr. Kheterpal’s office at (919)684-1830 for more information on this trial:
1. Basal Cell Nevus Syndrome: A Multicenter, Randomized, Double-blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects with Basal Cell Nevus Syndrome